A positive trend for triptorelin was also mentioned in the work of Uttley et al. presenting a summary of the Evidence Review Group (ERG) report on the company's submission (CS) for degarelix ( 24 ).
← all excerpts
Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes.
1
—
—